Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213665 | 0.88 | FFAR1 (0.37) | PPARGFFAR1 | |
| SCHEMBL14213672 | 0.87 | PPARG (0.38) | PPARGFFAR1 | |
| SCHEMBL14299379 | 0.87 | PPARG (0.50) | PPARGFFAR1 | |
| SCHEMBL14299380 | 0.85 | PPARG (0.39) | PPARGFFAR1 | |
| SCHEMBL17540553 | 0.83 | PPARG (0.39) | PPARGFFAR1NPC1RAB9ATDP1 | |
| SCHEMBL14213670 | 0.82 | FFAR1 (0.34) | PPARGFFAR1TDP1 | |
| SCHEMBL14213654 | 0.81 | FFAR1 (0.43) | PPARGFFAR1 | |
| SCHEMBL17540550 | 0.81 | PPARG (0.37) | PPARGFFAR1NPC1RAB9ATDP1 | |
| SCHEMBL14213690 | 0.78 | FFAR1 (0.33) | PPARGFFAR1TDP1 | |
| SCHEMBL14299383 | 0.75 | PPARG (0.55) | PPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885FFAR1 45/4885NPC1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.